三鑫医疗：生产线扩建、原材料采购等资金需求增加，公司对流动资金的需求日益显著

Core Viewpoint - Sanxin Medical (300453) announced on August 14 that it plans to expand its R&D and production base in Jiangxi to meet the growing market demand for blood dialysis products and to reserve new capacity for rapid expansion in new business areas such as vascular intervention [1] Group 1: Company Expansion Plans - The company aims to expand its production lines and procure raw materials to meet increasing working capital needs [1] - The expansion will support the annual production of 10 million blood dialysis membranes and 10 million blood dialysis devices [1] - New projects include the establishment of a production line for 30 million sets of high-performance blood purification equipment and supporting consumables [1] Group 2: Financing Strategy - The company plans to issue convertible bonds to raise no more than 530 million yuan, which will enhance its financial strength and optimize its asset structure [1] - The funds will be used for the expansion projects and to supplement working capital, thereby improving financial flexibility and reducing operational risks [1]